Tetramethylpyrazine nitrone, a multifunctional neuroprotective agent for ischemic stroke therapy

Area of Science:

• Neuroscience
• Pharmacology
• Biomedical Research

Background:

• Ischemic stroke remains a leading cause of death and disability worldwide.
• Current treatments are limited, necessitating the development of novel therapeutic agents.
• Tetramethylpyrazine derivatives, like TBN, exhibit free radical-scavenging properties.

Purpose of the Study:

• To evaluate the therapeutic efficacy of TBN in a non-human primate model of ischemic stroke.
• To investigate the neuroprotective and functional recovery effects of TBN.
• To identify molecular mechanisms underlying TBN's action.

Main Methods:

• Thirty male Cynomolgus macaques were induced with stroke (4 hours ischemia/reperfusion).
• TBN was administered intravenously at 3 or 6 hours post-ischemia.
• Cerebral infarction, neurological function, and protein markers were assessed using MRI, clinical scores, and quantitative proteomics.

Main Results:

• TBN penetrated the blood-brain barrier and achieved therapeutic concentrations.
• Significant reduction in cerebral infarction volume was observed.
• Modest preservation of neurological function in the affected arm was noted.
• TBN modulated neuroinflammatory markers (vimentin, GFAP), promoted myelination (2',3'-CNPase), and increased neuronal survival (NeuN).

Conclusions:

• TBN demonstrates significant neuroprotective effects in a primate stroke model.
• The compound effectively reduces infarct size and improves neurological outcomes.
• TBN's mechanisms involve suppressing neuroinflammation and promoting neuronal survival and myelination.
• TBN represents a promising clinical candidate for ischemic stroke treatment.